CHECKMATE-577

NCT02743494 📎

Regimen

Experimental
nivolumab for 1 year
Control
placebo

Population

R0 resected stage II/III esophageal/GEJ cancer with residual pathologic disease after neoadjuvant chemoradiotherapy

Key finding

mDFS 22.4 vs 11.0 mo (HR 0.69, 96.4% CI 0.56-0.86, P<0.001); OS signal later mature (restricted to PD-L1+, non-sig ITT at ASCO 2025)

Source: PMID 33789008

Timeline

    Guideline citations

    • NCCN GASTRIC (p.126)
    • CSCO GASTRIC 2025 (p.73)⚠️ OCR source